Literature DB >> 21325975

How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems.

Joseph M Pepek1, Junzo P Chino, Lawrence B Marks, Thomas A D'amico, David S Yoo, Mark W Onaitis, Neal E Ready, Jessica L Hubbs, Jessamy Boyd, Chris R Kelsey.   

Abstract

INTRODUCTION: To evaluate how well the tumor, node, metastasis (TNM) 6 and TNM 7 staging systems predict rates of local/regional recurrence (LRR) after surgery alone for non-small cell lung cancer.
METHODS: All patients who underwent surgery for non-small cell lung cancer at Duke between 1995 and 2005 were reviewed. Those undergoing sublobar resections, with positive margins or involvement of the chest wall, or those who received any chemotherapy or radiation therapy (RT) were excluded. Disease recurrence at the surgical margin, or within ipsilateral hilar and/or mediastinal lymph nodes, was considered as a LRR. Stage was assigned based on both TNM 6 and TNM 7. Rates of LRR were estimated using the Kaplan-Meier method. A Cox regression analysis evaluated the hazard ratio of LRR by stage within TNM 6 and TNM 7.
RESULTS: A total of 709 patients were eligible for the analysis. Median follow-up was 32 months. For all patients, the 5-year actuarial risk of LRR was 23%. Conversion from TNM 6 to TNM 7 resulted in 21% stage migration (upstaging in 13%; downstaging in 8%). Five-year rates of LRR for stages IA, IB, IIA, IIB, and IIIA disease using TNM 6 were 16%, 26%, 43%, 35%, and 40%, respectively. Using TNM 7, corresponding rates were 16%, 23%, 37%, 39%, and 30%, respectively. The hazard ratios for LRR were statistically different for IA and IB in both TNM 6 and 7 but were also different for IB and IIA in TNM 7.
CONCLUSIONS: LRR risk increases monotonically for stages IA to IIB in the new TNM 7 system. This information might be valuable when designing future studies of postoperative RT.

Entities:  

Mesh:

Year:  2011        PMID: 21325975     DOI: 10.1097/JTO.0b013e31821038c0

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors.

Authors:  Jyoti Malhotra; Salma K Jabbour; Sharon Pine
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Racial disparities in follow-up care of early-stage lung cancer survivors.

Authors:  Jyoti Malhotra; Lisa E Paddock; Yong Lin; Sharon R Pine; Muhammad H Habib; Antoinette Stroup; Sharon Manne
Journal:  J Cancer Surviv       Date:  2022-03-22       Impact factor: 4.442

3.  The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

Authors:  Simone de Leon Martini; Carolina Beatriz Müller; Rosalva Thereza Meurer; Marilda da Cruz Fernandes; Rodrigo Mariano; Mariel Barbachan E Silva; Fábio Klamt; Cristiano Feijó Andrade
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

4.  Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.

Authors:  David D Stenehjem; Brandon K Bellows; Kraig M Yager; Joshua Jones; Rajesh Kaldate; Uwe Siebert; Diana I Brixner
Journal:  Oncologist       Date:  2015-11-27

Review 5.  Clinical relevance of circulating cell-free microRNAs in cancer.

Authors:  Heidi Schwarzenbach; Naohiro Nishida; George A Calin; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675

6.  Prognostic value of microRNA expression in operable non-small cell lung cancer patients.

Authors:  M Skrzypski; P Czapiewski; K Goryca; E Jassem; L Wyrwicz; R Pawłowski; W Rzyman; W Biernat; J Jassem
Journal:  Br J Cancer       Date:  2014-01-21       Impact factor: 7.640

7.  Risk factors of postoperative recurrences in patients with clinical stage I NSCLC.

Authors:  Ying-Yi Chen; Tsai-Wang Huang; Wen-Chiuan Tsai; Li-Fan Lin; Jian-Bo Cheng; Hung Chang; Shih-Chun Lee
Journal:  World J Surg Oncol       Date:  2014-01-10       Impact factor: 2.754

8.  Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience.

Authors:  Manpreet Singh Tiwana; Hsueh Ni Lee; Sunil Saini; S K Verma; Meenu Gupta; Madhur Gupta; Navneet Jain; Girish Sindhwani; Jagdish Rawat; Manju Saini; Neena Chauhan; Dushyant Gaur
Journal:  Lung India       Date:  2013-07

9.  "One-stop shop" spectral imaging for rapid on-site diagnosis of lung cancer: a future concept in nano-oncology.

Authors:  Kaid Darwiche; Paul Zarogoulidis; Leslie Krauss; Filiz Oezkan; Robert Fred Henry Walter; Robert Werner; Dirk Theegarten; Leonidas Sakkas; Antonios Sakkas; Wolfgang Hohenforst-Scmidt; Konstantinos Zarogoulidis; Lutz Freitag
Journal:  Int J Nanomedicine       Date:  2013-11-22

Review 10.  Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer.

Authors:  Cecile Le Péchoux; Olaf Mercier; Deborah Belemsagha; Ryan Bouaita; Benjamin Besse; Elie Fadel
Journal:  EJC Suppl       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.